Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404

Premenopausal Breast Cancer ◽

Oncology Group Study ◽

Node Positive

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)

International Journal of Clinical Oncology ◽

10.1007/s10147-013-0657-z ◽

2014 ◽

Vol 19 (6) ◽

pp. 982-988 ◽

Cited By ~ 6

Author(s):

Tadahiko Shien ◽

Hiroji Iwata ◽

Kenjiro Aogi ◽

Takashi Fukutomi ◽

Kenichi Inoue ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Clinical Oncology ◽

Postmenopausal Breast Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Node Positive

Final Results of a Safety and Efficacy Trial of Preoperative Sequential Chemoradiation Therapy for the Nonsurgical Treatment of Early Breast Cancer: Japan Clinical Oncology Group Study JCOG0306

Oncology ◽

10.1159/000355196 ◽

2013 ◽

Vol 85 (6) ◽

pp. 336-341 ◽

Cited By ~ 8

Author(s):

Hirofumi Mukai ◽

Toru Watanabe ◽

Michihide Mitsumori ◽

Hitoshi Tsuda ◽

Seigo Nakamura ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Oncology ◽

Early Breast Cancer ◽

Chemoradiation Therapy ◽

Nonsurgical Treatment ◽

Oncology Group ◽

Efficacy Trial ◽

Oncology Group Study ◽

Safety And Efficacy

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)

10.1093/jjco/hyx063 ◽

2017 ◽

Vol 47 (7) ◽

pp. 664-667 ◽

Cited By ~ 8

Author(s):

Kenjiro Namikawa ◽

Arata Tsutsumida ◽

Tomonori Mizutani ◽

Taro Shibata ◽

Tatsuya Takenouchi ◽

...

Keyword(s):

Adjuvant Therapy ◽

Clinical Oncology ◽

Cutaneous Melanoma ◽

Interferon Beta ◽

Stage Ii ◽

Phase Iii ◽

Oncology Group ◽

Phase Iii Trial ◽

Oncology Group Study

Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208

Cancer Science ◽

10.1111/j.1349-7006.2007.00639.x ◽

2007 ◽

Vol 0 (0) ◽

pp. 071027181834001-???

Author(s):

Yutaka Tokuda ◽

Tomoo Tajima ◽

Masaru Narabayashi ◽

Kunihiko Takeyama ◽

Toru Watanabe ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Clinical Oncology ◽

High Dose Chemotherapy ◽

Phase Iii ◽

High Dose ◽

Oncology Group ◽

Oncology Group Study ◽

Phase Iii Study

Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508

International Journal of Hematology ◽

10.1007/s12185-012-1101-2 ◽

2012 ◽

Vol 96 (1) ◽

pp. 74-83 ◽

Cited By ~ 3

Author(s):

Yoshitoyo Kagami ◽

◽

Kuniaki Itoh ◽

Kensei Tobinai ◽

Haruhiko Fukuda ◽

...

Keyword(s):

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Study ◽

Hodgkin's Lymphoma ◽

Intermediate Risk ◽

Newly Diagnosed ◽

Oncology Group ◽

Oncology Group Study ◽

Chop Therapy

Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer: Japan Clinical Oncology Group study (JCOG1601, RESPOND)

10.1093/jjco/hyy125 ◽

2018 ◽

Cited By ~ 2

Author(s):

Kiyo Tanaka ◽

Nobuhiro Hanai ◽

Junko Eba ◽

Junki Mizusawa ◽

Takahiro Asakage ◽

...

Keyword(s):

Neck Dissection ◽

Clinical Oncology ◽

Tongue Cancer ◽

Stage I ◽

Phase Iii ◽

Oncology Group ◽

Oncology Group Study ◽

Phase Iii Study ◽

Prophylactic Neck Dissection

699 A Non-Randomized Confirmatory Trial of Endoscopic Submucosal Dissection to Expand Its Indication for Early Gastric Cancer (Ct1a): The Japan Clinical Oncology Group Study (Jcog0607)

Gastrointestinal Endoscopy ◽

10.1016/j.gie.2016.03.130 ◽

2016 ◽

Vol 83 (5) ◽

pp. AB164 ◽

Cited By ~ 1

Author(s):

Noriaki Hasuike ◽

Hiroyuki Ono ◽

Narikazu Boku ◽

Kohei Takizawa ◽

Junki Mizusawa ◽

...

Keyword(s):

Gastric Cancer ◽

Early Gastric Cancer ◽

Endoscopic Submucosal Dissection ◽

Clinical Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Submucosal Dissection ◽

Confirmatory Trial

A Randomized Phase II/III Trial Comparing Hepatectomy Followed by mFOLFOX6 with Hepatectomy Alone as Treatment for Liver Metastasis from Colorectal Cancer: Japan Clinical Oncology Group Study JCOG0603

10.1093/jjco/hyp035 ◽

2009 ◽

Vol 39 (6) ◽

pp. 406-409 ◽

Cited By ~ 37

Author(s):

Y. Kanemitsu ◽

T. Kato ◽

Y. Shimizu ◽

Y. Inaba ◽

Y. Shimada ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastasis ◽

Clinical Oncology ◽

Phase Ii ◽

Oncology Group ◽

Oncology Group Study ◽

Randomized Phase Ii

Randomized Controlled Trial to Evaluate Radiotherapy Endocrine Therapy Versus Endocrine Therapy Alone for PSA Failure after Radical Prostatectomy: Japan Clinical Oncology Group Study JCOG 0401

10.1093/jjco/hyi007 ◽

2005 ◽

Vol 35 (1) ◽

pp. 34-36 ◽

Cited By ~ 13

Author(s):

A. Yokomizo

Keyword(s):

Randomized Controlled Trial ◽

Radical Prostatectomy ◽

Endocrine Therapy ◽

Clinical Oncology ◽

Controlled Trial ◽

Oncology Group ◽

Oncology Group Study ◽

Randomized Controlled ◽

Psa Failure

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive biomarkers of pathologic complete response (pCR) in neoadjuvant breast cancer: an Irish Clinical Oncology Group study (ICORG 16-20)

Annals of Oncology ◽

10.1093/annonc/mdw392.20 ◽

2016 ◽

Vol 27 ◽

pp. vi532 ◽

Cited By ~ 1

Author(s):

S. Rafee ◽

D.J. McHugh ◽

M. Greally ◽

O. Ayodele ◽

N. Keegan ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Oncology ◽

Pathologic Complete Response ◽

Predictive Biomarkers ◽

Complete Response ◽

Neutrophil To Lymphocyte Ratio ◽

Oncology Group ◽

Platelet To Lymphocyte Ratio ◽

Oncology Group Study ◽

Lymphocyte Ratio